Pharmaceuticals Companies By Operating Cash Flow

Cash Flow From Operations
Cash Flow From OperationsEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
716.34 B
(0.12)
 0.90 
(0.10)
2NVO Novo Nordisk AS
108.91 B
(0.20)
 1.80 
(0.37)
3RDY Dr Reddys Laboratories
45.43 B
(0.16)
 1.28 
(0.21)
4JNJ Johnson Johnson
22.79 B
(0.13)
 0.78 
(0.10)
5NVS Novartis AG ADR
14.46 B
(0.18)
 0.97 
(0.18)
6BMY Bristol Myers Squibb
13.86 B
 0.14 
 2.00 
 0.29 
7MRK Merck Company
13.01 B
(0.17)
 1.20 
(0.20)
8AZN AstraZeneca PLC ADR
10.35 B
(0.24)
 1.52 
(0.36)
9SNY Sanofi ADR
10.26 B
(0.22)
 1.18 
(0.26)
10PFE Pfizer Inc
8.7 B
(0.06)
 1.42 
(0.09)
11GSK GlaxoSmithKline PLC ADR
6.77 B
(0.24)
 1.47 
(0.35)
12LLY Eli Lilly and
4.24 B
(0.14)
 1.91 
(0.27)
13RPRX Royalty Pharma Plc
2.99 B
(0.11)
 1.00 
(0.11)
14VTRS Viatris
2.8 B
 0.08 
 2.29 
 0.18 
15ZTS Zoetis Inc
2.35 B
(0.05)
 1.31 
(0.06)
16TEVA Teva Pharma Industries
1.37 B
(0.08)
 1.79 
(0.14)
17JAZZ Jazz Pharmaceuticals PLC
1.09 B
 0.10 
 1.95 
 0.19 
18BHC Bausch Health Companies
1.03 B
 0.17 
 3.20 
 0.56 
19OGN Organon Co
799 M
(0.23)
 2.05 
(0.47)
20PRGO Perrigo Company PLC
405.5 M
 0.02 
 1.93 
 0.03 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings. Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.